Recordati stock enters new phase after nine-month update

Published on 11/12/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Recordati stock enters a new phase after the company reported solid nine-month growth. Management kept its 2026 targets at the upper end of guidance.

Recordati reports resilient nine-month growth

Revenue and EBITDA increased in the first nine months of 2026, led by the Rare Diseases business.
Management expects full-year 2026 targets to land at the upper end of the guidance ranges.
The board will not pay an interim dividend as the squeeze-out and delisting process advances.

Recordati, IT0003828271, Illustration mit AI erstellt.

Recordati reported stronger nine-month operating results on Tuesday, November 10, while its takeover process moved toward a squeeze-out and delisting from Euronext Milan. The company said in its November 10 company announcement that full-year targets should land at the upper end of their guidance ranges.

Growth led by Rare Diseases

Consolidated revenue reached 2,103.7 million euros in the first nine months of 2026, up 7.5 percent from the prior-year period. EBITDA rose 7.7 percent to 801.1 million euros, while adjusted net income increased 6.4 percent to 524.9 million euros.

Rare Diseases remained the main growth engine, with revenue up 18.7 percent to 928.2 million euros. Isturisa revenue advanced 54.8 percent to 285.9 million euros, while Specialty and Primary Care revenue increased 0.5 percent to 1,135.5 million euros. Foreign-exchange effects reduced revenue by 35.6 million euros.

Targets and shareholder payments

Recordati confirmed 2026 revenue guidance of 2,730 million to 2,800 million euros, EBITDA guidance of 995 million to 1,030 million euros and adjusted net income guidance of 655 million to 685 million euros. The company expects to finish each range at the upper end.

The board also decided not to distribute an interim dividend for 2026 because the 53-euro tender offer is cum dividend and the squeeze-out is approaching. Final results from the reopened offer are due by 7:29 a.m. on Monday, November 16, with settlement scheduled for Tuesday, November 17.

Shareholders await the final steps

Recordati stock traded at 52.50 euros on Lang & Schwarz at 17:39:41 CET on Thursday, November 12, 2026. The remaining investor focus is on the final offer results, the compulsory acquisition process and the planned removal of the shares from Euronext Milan.